Monoclonal Antibody in Kidney Transplantation
نویسندگان
چکیده
منابع مشابه
Kidney Transplantation in Iran
Kidney transplantation in patients with end stage renal disease is preferred to dialysis because transplantation provides a better quality of life andimproved survival. However, the gap between the supply and demand for a renal allograft is widening and the waiting time is increasing. Iranian protocol, a controlled transplant program supported by the government for living unrelated donors, was ...
متن کاملOfatumumab Monoclonal Antibody Affinity Maturation Through in silico Modeling
Background: Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody-dependent phagocytosis by macrophages. Apoptosis induction is another mechanism of this antibody...
متن کاملMonoclonal Antibody Therapy and Renal Transplantation: Focus on Adverse Effects
A series of monoclonal antibodies (mAbs) are commonly utilized in renal transplantation as induction therapy (a period of intense immunosuppression immediately before and following the implant of the allograft), to treat steroid-resistant acute rejections, to decrease the incidence and mitigate effects of delayed graft function, and to allow immunosuppressive minimization. Additionally, in the ...
متن کاملMonoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma.
Forty patients with plasma cell dyscrasias underwent high-dose chemoradiotherapy and either anti-B-cell monoclonal antibody (MoAb)-treated autologous, anti-T-cell MoAb-treated HLA-matched sibling allogeneic or syngeneic bone marrow transplantation (BMT). The majority of patients had advanced Durie-Salmon stage myeloma at diagnosis, all were pretreated with chemotherapy, and 17 had received prio...
متن کاملAntibody-mediated rejection in kidney transplantation: an update.
INTRODUCTION Acute antibody-mediated rejection (AMR) in renal-transplant recipients is generally less responsive to conventional antirejection therapy and has a worse prognosis than acute cellular rejection. AREAS COVERED This review provides a broad understanding of the pathogenesis of AMR, recent advances in its therapy, and future directions. Conventional therapeutic approaches to AMR have...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Juntendo Medical Journal
سال: 1983
ISSN: 0022-6769,2188-2134
DOI: 10.14789/pjmj.29.314